pharmaceuticals
pharmaceuticals Articles
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked...
Published:
Last Updated:
Nymox Pharmaceutical shares made solid headway in Wednesday’s session on positive results from a cancer trial.
Published:
Last Updated:
Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
Published:
Last Updated:
Global Blood Therapeutics shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level.
Published:
Last Updated:
Selecta Biosciences intends to price more than 4 million shares in the range of $14 to $16 per share for an initial public offering valued up to more than $78 million.
Published:
Last Updated:
Syros Pharmaceuticals expects to price 4 million shares in the range of $14 to $16 per share in an intial public offering valued up to more than $73 million.
Published:
Last Updated:
Inovio Pharmaceuticals has announced that it received approval to initiate a Phase 1 human trial to evaluate its Zika DNA vaccine (GLS-5700) to prevent infection from the Zika virus.
Published:
Last Updated:
Shares of Fate Therapeutics saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval.
Published:
Last Updated:
Paratek Pharmaceuticals saw its shares take a solid jump early on Friday after the results from its late-stage trial were released.
Published:
Last Updated:
Shares of Tonix Pharmaceuticals slid in Thursday’s session after the company announced the pricing of its secondary offering.
Published:
Last Updated:
24/7 Wall St. has picked out the biggest movers and winners on Wednesday, particularly biopharma companies making serious runs in the session.
Published:
Last Updated:
Revance Therapeutics hit a new 52-week low in Tuesday’s session following the release of its late stage trial results.
Published:
Last Updated:
Though Infinity Pharmaceuticals announced that its DYNAMO study met its primary endpoint of overall response rate, the stock was still way down on the day for other reasons.
Published:
Last Updated:
Pfizer made waves early on Tuesday after it announced a new licensing deal with Shire for an investigational biologic.
Published:
Last Updated:
With the market looking decidedly overbought, one good idea is to rotate to stocks that may have lagged but still have solid upside potential.
Published:
Last Updated: